Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Conditions

Pain 9Neoplasms 6Cancer Pain 5Marijuana Abuse 2Signs and Symptoms 1Parasomnias 1Neuralgia 1Nausea 1Multiple Sclerosis 1Marijuana Use 1Diabetes Mellitus 1Anxiety Disorders 11- Cancer Patients During Chemotherapy Treatment 1

Interventions

Nutrition Assessment 3Metformin 3Tablets 2Resistance Training 2Pioglitazone 2Methods 2Exercise 2Educational Status 2otelixizumab 1nabiximols 1Verapamil 1Therapeutics 1Surveys and Questionnaires 1Specimen Handling 1Risk Assessment 1Remote Consultation 1Pancreas, Artificial 1Palliative Care 1Lysine Acetyltransferase 5 1Jogging 1Interviews as Topic 1Gastrectomy 1Fish Oils 1Endoscopic Mucosal Resection 1Eating 1Docosahexaenoic Acids 1Diet, Mediterranean 1Diet, Fat-Restricted 1Diet, Carbohydrate-Restricted 1DM199 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Diabetes Mellitus × nabiximols × Clear all
NCT02073474 2022-12-20

An Observational Post-Marketing Safety Registry of Sativex®

Jazz Pharmaceuticals

Completed
978 enrolled

Marijuana Abuse, Diabetes Mellitus, Multiple Sclerosis, Neoplasms, Neuralgia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡